Search

Your search keyword '"Aarsland, Dag"' showing total 730 results

Search Constraints

Start Over You searched for: Author "Aarsland, Dag" Remove constraint Author: "Aarsland, Dag" Database Unpaywall Remove constraint Database: Unpaywall
730 results on '"Aarsland, Dag"'

Search Results

5. Cerebrovascular co-pathology and cholinergic white matter pathways along the Lewy body continuum

6. The SLaM Brain Health Clinic: a remote biomarker enhanced memory clinic for patients with mild cognitive impairment within an NHS mental health trust

7. Grey matter networks in women and men with dementia with Lewy bodies

8. Neutrophil-to-lymphocyte ratio and lymphocyte count as an alternative to body mass index for screening malnutrition in older adults living in the community

10. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

14. Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)

15. Meeting summary of The NYO3 5th NO-Age/AD meeting and the 1st Norway-UK joint meeting on ageing and dementia: recent progress on the mechanisms and interventional strategies

16. Nutrient Intake and its Association with Appendicular Total Lean Mass, Function and Strength in Older Adults: A Population-Based Study

17. Differential methylation analysis in neuropathologically confirmed dementia with Lewy bodies

19. Temporal Muscle Thickness: A Practical Approximation for Assessing Muscle Mass in Older Adults

20. Linking sarcopenia, brain structure and cognitive performance: a large-scale UK Biobank study

21. Sex differences in brain atrophy in dementia with Lewy bodies

24. Using magnetic resonance imaging to measure head muscles: An innovative method to opportunistically determine muscle mass and detect sarcopenia

26. CSF AβX‐34 ‐ a new biomarker for amyloid‐related small vessel pathology in early Alzheimer’s Disease

29. Grey matter alterations associated with the phenomenology of visual hallucinations in Lewy Body Disease

35. CSF synapse marker changes in predementia Alzheimer´s Disease: AMPA receptor modulators NPTX2 and NPTXR mediate cognition within A/T/N stages

37. A multimodal digital biomarker of functional deficits in early‐stage Alzheimer’s disease: results of the RADAR‐AD study

38. 4. An innovative clinical trial designed to evaluate the effects of ACI‐24.060 in Alzheimer’s Disease and in Down syndrome (ABATE Study)

40. Progress on the Development of the Lewy Body Dementia‐Domain Rating Scale

43. Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission

44. Cognitive decline in older adults in the UK during and after the COVID-19 pandemic: a longitudinal analysis of PROTECT study data

45. Specific neuropsychiatric symptoms are associated with functional decline trajectories in Alzheimer’s disease and Lewy body dementia: a five-year follow-up study

46. Developing a core outcome set (COS) for Dementia with Lewy bodies (DLB)

48. Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment

49. Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment

Catalog

Books, media, physical & digital resources